Cargando…

654: A THIRD DOSE OF SARS-COV-2 VACCINE YIELDS HIGH ANTIBODY LEVELS COMPARED TO TWO DOSE VACCINATION SCHEDULE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Detalles Bibliográficos
Autores principales:	Quan, Joshua, Ma, Christopher, Panaccione, Remo, Kanji, Jamil, Charlton, Carmen, Tipples, Graham, Sharifi, Nastaran, Herauf, Michelle, Markovinovic, Ante, Turnbull, LeeAnn, Bernatsky, Sasha, Bindra, Gurmeet K., Mahoney, Douglas, Ingram, Richard J., Hracs, Lindsay, Coward, Stephanie, Windsor, Joseph W., Buie, Michael J., Chan, Melissa, Ferraz, Jose G., Lu, Cathy, Mathivanan, Meena, Novak, Kerri L., Seow, Cynthia H., Shukla, Tushar, Kaplan, Gilaad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AGA Institute. Published by Elsevier Inc. 2022
Materias:	AGA Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212277/ http://dx.doi.org/10.1016/S0016-5085(22)60385-8

Ejemplares similares

Su1484: SEROLOGICAL RESPONSES TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE COHORT STUDY
por: Quan, Joshua, et al.
Publicado: (2022)

SEROLOGICAL RESPONSES TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE COHORT STUDY
por: Quan, Joshua, et al.
Publicado: (2022)

Serological responses to the first four doses of SARS-CoV-2 vaccine in patients with inflammatory bowel disease
por: Quan, Joshua, et al.
Publicado: (2022)

A195 DURABILITY OF SEROLOGICAL RESPONSES AFTER SECOND, THIRD AND FOURTH DOSE OF SARS-COV-2 VACCINATION IN INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE COHORT STUDY
por: Sharifi, N, et al.
Publicado: (2023)

Serological responses to three doses of SARS-CoV-2 vaccination in inflammatory bowel disease
por: Quan, Joshua, et al.
Publicado: (2023)

Adverse Events and Serological Responses After SARS-CoV-2 Vaccination in Individuals With Inflammatory Bowel Disease
por: Markovinović, Ante, et al.
Publicado: (2023)

A170 ADVERSE EVENTS & SEROLOGICAL RESPONSES FOLLOWING SARS-COV-2 VACCINATION IN INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASE
por: Markovinovic, A, et al.
Publicado: (2023)

Antibody response to SARS-CoV-2 among individuals with IBD diminishes over time: a serosurveillance cohort study
por: Kaplan, Gilaad G, et al.
Publicado: (2022)

Fr099 HEALTHCARE PROVIDER SATISFACTION WITH VIRTUAL CARE DELIVERY IN ALBERTA DURING THE COVID-19 PANDEMIC.
por: Olayinka, Lily, et al.
Publicado: (2021)

Fr098 IMPACT OF COVID-19 PANDEMIC IN IBD PATIENT CARE
por: Dahiya, Monica, et al.
Publicado: (2021)

656: POST-VACCINATION SYMPTOMS AFTER A THIRD DOSE OF SARS-COV-2 MRNA VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Mujukian, Angela, et al.
Publicado: (2022)

A193 DEMOGRAPHIC, SOCIAL AND OCCUPATIONAL FACTORS THAT PREVENTED EXPOSURE TO SARS-COV-2 IN INFLAMMATORY BOWEL DISEASE PATIENTS DURING THE COVID-19 PANDEMIC: A PROSPECTIVE COHORT STUDY
por: Caplan, L N, et al.
Publicado: (2023)

Su1489: HUMORAL IMMUNOGENICITY OF THREE SARS-COV-2 MRNA VACCINE DOSES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Schell, Trevor, et al.
Publicado: (2022)

Su1492: STRONG HUMORAL IMMUNE RESPONSE TO SARS-COV-2 VACCINE ADDITIONAL DOSE AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASES
por: Kappelman, Michael, et al.
Publicado: (2022)

94: ANTIBODY RESPONSE AFTER A BOOSTER DOSE OF SARS-COV-2 VACCINE IN LIVER TRANSPLANT RECIPIENTS AND THOSE WITH CHRONIC LIVER DISEASES
por: Chauhan, Mahak, et al.
Publicado: (2022)

Sa1052: IMMUNOGENICITY AND SAFETY OF STANDARD AND THIRD DOSE SARS-COV-2 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES; A PROSPECTIVE COHORT STUDY
por: Joergensen, Kristin K., et al.
Publicado: (2022)

Sa1050: COVID-19 VACCINATION RATES AND POST-VACCINATION INFECTION RISK IN IBD PATIENTS TREATED WITH DISEASE MODIFYING AGENTS: A RESEARCH NETWORK ANALYSIS
por: Chumbe, Julton Tomanguillo, et al.
Publicado: (2022)

Fr581 EVALUATION OF SEQUENTIAL CHANGES IN THE INTESTINAL FLORA OF PATIENTS TAKING LOW-DOSE ASPIRIN AND A PROTON-PUMP INHIBITOR
por: Hirata, Yuki, et al.
Publicado: (2021)

Fr228 AN INTERNATIONAL REPORTING REGISTRY OF PATIENTS WITH CELIAC DISEASE AND COVID-19: INITIAL RESULTS FROM SECURE-CELIAC
por: Uche-Anya, Eugenia, et al.
Publicado: (2021)

1165: SARS-COV-2 VACCINATION INDUCES A PREDOMINENTLY CLASS II (CYTOKINE EFFECTOR) T CELL RESPONSE, BUT THE CLASS I RESPONSE IS AUGMENTED BY ANTI-TNF THERAPY AND VACCINE TYPE
por: Xu, Alexander, et al.
Publicado: (2022)

EP1270: SEROCONVERSION IN INFLAMMATORY BOWEL DISEASE PATIENTS AFTER COVID-19 VACCINATION
por: Horvath, Miklos, et al.
Publicado: (2022)

Tu1544: HUMORAL AND T CELL RESPONSES TO COVID-19 VACCINATION IN INFLAMMATORY BOWEL DISEASE
por: Zhang, Eva, et al.
Publicado: (2022)

Su1495: COVID-19 VACCINE HESITANCY REMAINS HIGH IN INFLAMMATORY BOWEL DISEASE PATIENTS
por: Kwon, Hyuk Joon, et al.
Publicado: (2022)

Su1491: ATTITUDES AND PREDICTORS OF COVID-19 VACCINE UPTAKE IN INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASE
por: Zhang, Eva, et al.
Publicado: (2022)

Su1498: SAFETY OF COVID-19 VACCINATION IN INFLAMMATORY BOWEL DISEASE PATIENTS ON BIOLOGIC THERAPY
por: Garrido, Isabel, et al.
Publicado: (2022)

Fr493 DISEASE ACTIVITY IS ASSOCIATED WITH COVID-19 OUTCOMES IN IBD PATIENTS WITH EFFECT MODIFICATION BY AGE
por: Ricciuto, Amanda, et al.
Publicado: (2021)

Su1003: IMPACT OF THE COVID-19 PANDEMIC ON HEALTHCARE ACCESS, DELIVERY AND VACCINATION IN PATIENTS WITH DIGESTIVE DISORDERS
por: Russin, Michelle, et al.
Publicado: (2022)

AGA Rapid Review and Guideline for SARS-CoV2 Testing and Endoscopy Post-Vaccination: 2021 Update
por: Sultan, Shahnaz, et al.
Publicado: (2021)

Su1487: IMPACT OF INFLAMMATORY BOWEL DISEASE THERAPIES ON DURABILITY OF HUMORAL RESPONSE TO SARS COV-2 VACCINATION
por: Charilaou, Paris, et al.
Publicado: (2022)

Tu1547: COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Meybodi, Mohamad Aghaie, et al.
Publicado: (2022)

Su1483: COVID-19 VACCINES ARE HIGHLY EFFECTIVE IN PATIENTS WITH IBD: OUTCOMES FROM THE SCOUT IBD COHORT
por: Hong, Simon J., et al.
Publicado: (2022)

Fr509 COVID-19 OUTCOMES AMONG RACIAL AND ETHNIC MINORITY INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASES IN THE UNITED STATES
por: Agrawal, Manasi, et al.
Publicado: (2021)

Mo1020: GUT MICROBIOME CHANGES ASSOCIATED WITH HIGHER AND LONGER-LASTING ANTIBODY TITERS FOLLOWING COVID-19 VACCINATION
por: Venzon, Mericien M., et al.
Publicado: (2022)

Sa1063: COVID AND COVID VACCINATION AMONG OUTPATIENTS WITH FUNCTIONAL GI AND GI MOTILITY DISORDERS; EFFECTS ON GI SYMPTOMS.
por: Silver, Paul, et al.
Publicado: (2022)

Su1497: EFFECT OF SARS COV-2 VACCINE IN IBD PATIENTS ON BIOLOGIC THERAPY INCLUDING LIVER TRANSPLANT RECIPIENTS.
por: Brezina, Jan, et al.
Publicado: (2022)

EP1271: UNPLANNED HOPSITAL ADMISSION AND EMERGENCY ATTENDANCE FOLLOWING TWO-DOSE OF BNT162B2 AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A POPULATION-BASED COHORT STUDY
por: Li, Xue, et al.
Publicado: (2022)

653: PATIENTS WITH INFLAMMATORY BOWEL DISEASE HAVE IMPAIRED HUMORAL BUT PRESERVED CELLULAR RESPONSES TO SARS-COV-2 MRNA VACCINATION
por: Li, Dalin, et al.
Publicado: (2022)

Tu1550: REAL WORLD USE AND ADVERSE EVENTS OF SARS-COV-2 VACCINATION IN GREEK PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Orfanoudaki, Eleni, et al.
Publicado: (2022)

Tu1552: PRESERVED SARS-COV-2 VACCINE CELL-MEDIATED IMMUNOGENICITY IN INFLAMMATORY BOWEL DISEASE PATIENTS ON IMMUNEMODULATING THERAPIES
por: Boland, Brigid S., et al.
Publicado: (2022)

Su1485: COVID-19 VACCINE-INDUCED ANTIBODY RESPONSES ARE IMPAIRED IN IBD PATIENTS TREATED WITH INFLIXIMAB, USTEKINUMAB OR TOFACITINIB, BUT NOT THIOPURINES OR VEDOLIZUMAB
por: Alexander, James L., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_282i18qmos01douf2rft28rjel